Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

At Admission Serum Presepsin as Early Predictor for Disease Severity and Positive Blood Culture for Neonates With Early-onset Sepsis

NCT05022043 is registered in ClinicalTrials.gov with Tanta University as lead sponsor.

NCT NCT05022043
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05022043 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
At Admission Serum Presepsin as Early Predictor for Disease Severity and Positive Blood Culture for Neonates With Early-onset Sepsis
Lead sponsor
Tanta University
Phase
Not applicable
Overall status
Completed
Start date
March 1, 2019
Completion date
June 15, 2021
Enrollment
124 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neonatal sepsis